UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
June
27,
2008
Date
of
Report (Date of earliest event reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
|
State
of New York
|
1-10113
|
11-0853640
|
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
|
of
Incorporation)
|
|
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e-4(c))
|
| Item 8.01 |
Other
Events
|
On
June
27, 2008 we received a $5.0
million milestone payment from King
Pharmaceuticals Research and Development, Inc, a wholly-owned subsidiary of
King
Pharmaceuticals, Inc., pursuant to a License, Development and Commercialization
Agreement between King and us, dated as of October 30, 2007, for
successfully achieving the primary end points in our pivotal Phase III study,
AP-ADF-105.
A
copy of
the press release issued by us is being furnished as Exhibit 99.1.
| Item9.01 |
Financial
Statements and Exhibits
|
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release of the Registrant dated June 30,
2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
ACURA
PHARMACEUTICALS, INC.
|
||
|
By:
|
/s/
Peter Clemens
|
|
|
Peter
A. Clemens
|
||
|
Senior
Vice President & Chief Financial
Officer
|
||
Date: June
27,
2008
EXHIBIT
INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release of the Registrant dated June 30,
2008.
|
